Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

NCT00392691 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: ibritumomab tiuxetan
DRUG: rituximab
DRUG: melphalan
DRUG: vinorelbine tartrate / G-CSF
PROCEDURE: autologous hematopoietic stem cell harvesting and transplantation

Sponsor

Swiss Cancer Institute